References
- Grimbizis G, Tsalikis T, Tzioufa V, et al. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: A prospective study. Hum Reprod 1999;14:479-84
- Baanders-van Halewyn EA, Blankenstein MA, Thijssen JH, et al. A comparative study of risk factors for hyperplasia and cancer of the endometrium. Eur J Cancer Prev 1996;5:105-12
- Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), as a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286-91
- Bajetta E, Zilembo N, Dowsett M, et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 1999;35:208-13
- Agorastos T, Vaitsi V, Pantazis K, et al. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005;118:239-40
- Nasri MN, Shepherd JH, Setchell ME, et al. The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynaecol 1991;98:470-5
- Varma R, Soneja H, Bhatia K, et al. The effectiveness of a levonorgestrel-releasing intrauterine system(LNG-IUS) in the treatment of endometrial hyperplasia – a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169-75
- Ørbo A, Arnes M, Hancke C, et al. Treatment results of endometrial hyperplasia after prospective D-score classification. A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68-73
- Garuti G, Cellani F, Centinaio G, et al. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. Gynecol Oncol, 2006;103:599-603